Skip to main content

Greenwich LifeSciences, Inc. (GLSI)

NASDAQ: GLSI · IEX Real-Time Price · USD
41.95 -3.21 (-7.11%)
Sep 24, 2021 2:29 PM EDT - Market open
Market Cap566.62M
Revenue (ttm)n/a
Net Income (ttm)-2.75M
Shares Out12.97M
EPS (ttm)-0.24
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume51,192
Open44.52
Previous Close45.16
Day's Range41.51 - 44.88
52-Week Range3.26 - 158.07
Betan/a
AnalystsBuy
Price Target76.50 (+82.4%)
Est. Earnings Daten/a

About GLSI

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Staffo...

IndustryBiotechnology
IPO DateSep 25, 2020
Employees1
Stock ExchangeNASDAQ
Ticker SymbolGLSI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for GLSI stock is "Buy." The 12-month stock price forecast is 76.50, which is an increase of 82.36% from the latest price.

Price Target
$76.50
(82.36% upside)
Analyst Consensus: Buy

News

Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference

1 day ago - Business Wire

Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

1 week ago - Business Wire

Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments

2 weeks ago - Business Wire

Greenwich LifeSciences to Participate in Citi's 16th Annual Biopharma Virtual Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Citi's 16th Annual Biopharma Virtual Conference

2 weeks ago - Business Wire

Greenwich LifeSciences Set to Join Russell 2000® Index

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Set to Join Russell 2000® Index

3 months ago - Business Wire

Greenwich LifeSciences' Breast Cancer Vaccine Unveils Five Year Data, Confirming to Prevent Metastatic Breast Cancer ...

Greenwich LifeSciences Inc (NASDAQ: GLSI) presented five-year data from Phase 2 breast cancer clinical trial evaluating GP2 immunotherapy in patients who have previously undergone surgery. Data were pre...

3 months ago - Benzinga

Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming th...

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming GP2 Treatment is Well Tolerated

3 months ago - Business Wire

1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?

The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?

5 months ago - The Motley Fool

Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commerc...

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization

5 months ago - Business Wire

Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting

5 months ago - Business Wire

Why Greenwich LifeSciences Stock Tanked Today

The drop came despite the clinical-stage biotech announcing good news over the weekend.

5 months ago - The Motley Fool

REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP...

STAFFORD, Texas--(BUSINESS WIRE)--GLSI's Immune Response Data Shows Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer

5 months ago - Business Wire

Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity...

STAFFORD, Texas--(BUSINESS WIRE)--GLSI's Immune Response Data Shows Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer

5 months ago - Business Wire

Why Greenwich LifeSciences Stock Is Rising Today

The company reported positive data for its cancer immunotherapy candidate GP2.

5 months ago - The Motley Fool

What's Going On With GLSI Stock And PSMT Stock Today?

Greenwich Lifesciences Inc (NASDAQ: GLSI) shares are trading higher by more than 15% after the company reported a robust immune response from its Phase 2b data supporting the GP2 clinical outcome of 0% ...

Other symbols:PSMT
5 months ago - Benzinga

Greenwich LifeSciences' Stock Is Trading Higher After Breast Cancer Immunotherapy Shows 0% Recurrences Over 5 Years F...

Greenwich LifeSciences Inc (NASDAQ: GLSI) has announced the abstract results of the final 5-year immune response data of the Phase 2b trial at the 2021 AACR Annual Meeting.  The company plans to publish...

5 months ago - Benzinga

Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic...

STAFFORD, Texas--(BUSINESS WIRE)--GLSI Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years Follow-up

5 months ago - Business Wire

Greenwich LifeSciences Is Both a Sound Investment and a Feel-Good Buy

Greenwich LifeSciences is advancing cancer treatments with life-changing potential, and recent developments should boost GLSI stock's value. The post Greenwich LifeSciences Is Both a Sound Investment an...

5 months ago - InvestorPlace

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...

New York, New York--(Newsfile Corp. - March 24, 2021) - Levi & Korsinsky announces it has commenced an investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning possible breaches of fiduci...

5 months ago - Newsfile Corp

Greenwich LifeSciences Could See Another Spike in Stock in Early April

On December 8, 2020, Greenwich LifeSciences (NASDAQ: GLSI) share price closed at $5.20 per share. Greenwich LifeSciences published its 5-year breast cancer data from a Phase IIb trial at the San Antonio...

6 months ago - Benzinga

Exclusive: Greenwich LifeSciences CEO Calls Stock's Meteoric Rise 'Very Emotional'

Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a biopharmaceutical company that is developing GP2, an immunotherapy to prevent breast cancer recurrences in certain patients. The stock skyrocketed nearly...

6 months ago - Benzinga

Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for C...

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for Cancer Research Annual Meeting

6 months ago - Business Wire

Greenwich LifeSciences CEO to be Interviewed Live on Benzinga's Power Hour

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO to be Interviewed Live on Benzinga's Power Hour - Interview will air on Thursday, March 11, 2021 at 12:30 pm EST

6 months ago - Business Wire

Why Greenwich LifeSciences Stock Skyrocketed Today

Investors cheered an important new hire.

6 months ago - The Motley Fool

GLSI Stock: Why Greenwich LifeSciences Is Skyrocketing Today

GLSI stock is skyrocketing again on Monday after the company appointed Dr. Jaye Thompson to run its Phase 3 clinical trials. The post GLSI Stock: Why Greenwich LifeSciences Is Skyrocketing Today appeare...

6 months ago - InvestorPlace